Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

Background Topotecan has been shown In previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription. Purpose Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 1993-09, Vol.85 (18), p.1499-1507
Hauptverfasser:	Saltz, Leonard, Sirott, Matthew, Young, Charles, Tong, William, Niedzwiecki, Donna, Tzy-Jyun, Yao, Tao, Yue, Trochanowski, Bonnie, Wright, Patricia, Barbosa, Karen, Toomasi, Frieda, Kelsen, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Camptothecin - administration & dosage Camptothecin - analogs & derivatives Camptothecin - pharmacokinetics Camptothecin - therapeutic use Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Drug therapy Female Granulocyte Colony-Stimulating Factor - therapeutic use Humans Male Medical research Medical sciences Middle Aged Neoplasms - drug therapy Pharmacology Pharmacology. Drug treatments Recombinant Proteins Structure-Activity Relationship Topotecan Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!